INVIVYD, INC. Capital Expenditures
INVIVYD, INC. (IVVD) reported Capital Expenditures of $1.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-13
- INVIVYD, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $510.00K, a 4536.36% increase year-over-year.
- INVIVYD, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $726.00K, a 404.17% increase year-over-year.
- INVIVYD, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $0.00.
- INVIVYD, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- INVIVYD, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $155.00K, a 10.71% increase from fiscal 2024.
- INVIVYD, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $140.00K, a 77.24% decline from fiscal 2023.
- INVIVYD, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $615.00K, a 63.93% decline from fiscal 2022.
- INVIVYD, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $1.71M.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 7 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $510.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.24M 10-Q · filed 2026-08-13 | $1.24M derived: sum of 3 quarters · filed 2026-08-13 | $1.24M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $726.00K 10-Q · filed 2026-05-14 | $726.00K derived: sum of 2 quarters · filed 2026-05-14 | $726.00K derived: sum of 3 quarters · filed 2026-05-14 | $737.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $11.00K derived: sum of 3 quarters · filed 2026-08-13 | $155.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $11.00K derived: sum of 2 quarters · filed 2026-08-13 | $155.00K 10-Q · filed 2025-11-06 | $150.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $155.00K 10-Q · filed 2026-08-13 | $150.00K derived: sum of 3 quarters · filed 2026-08-13 | $155.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $144.00K 10-Q · filed 2026-05-14 | $139.00K derived: sum of 2 quarters · filed 2026-05-14 | $144.00K derived: sum of 3 quarters · filed 2026-05-14 | $144.00K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $140.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.00K derived: sum of 2 quarters · filed 2025-11-06 | $145.00K 10-Q · filed 2025-11-06 | $145.00K derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $140.00K 10-Q · filed 2025-08-14 | $140.00K derived: sum of 3 quarters · filed 2025-08-14 | $140.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $140.00K 10-Q · filed 2025-05-15 | $140.00K derived: sum of 2 quarters · filed 2025-05-15 | $140.00K derived: sum of 3 quarters · filed 2025-05-15 | $131.00K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | -$9.00K derived: sum of 3 quarters · filed 2025-03-20 | $615.00K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$9.00K derived: sum of 2 quarters · filed 2024-11-14 | $615.00K 10-Q · filed 2024-11-14 | $1.83M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $615.00K 10-Q · filed 2024-08-14 | $1.83M derived: sum of 3 quarters · filed 2024-08-14 | $2.30M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $624.00K 10-Q · filed 2024-05-09 | $1.83M derived: sum of 2 quarters · filed 2024-05-09 | $2.31M derived: sum of 3 quarters · filed 2024-05-09 | $2.33M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.69M derived: sum of 2 quarters · filed 2024-03-28 | $1.71M derived: sum of 3 quarters · filed 2024-03-28 | $1.71M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $477.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $494.00K derived: sum of 2 quarters · filed 2023-11-09 | $494.00K 10-Q · filed 2023-11-09 | $578.00K derived: sum of 4 quarters · filed 2024-02-09 | |
| 2022-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $17.00K 10-Q · filed 2023-08-10 | $101.00K derived: sum of 3 quarters · filed 2024-02-09 | $101.00K derived: sum of 4 quarters · filed 2024-02-09 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $84.00K derived: sum of 2 quarters · filed 2024-02-09 | $84.00K derived: sum of 3 quarters · filed 2024-02-09 | ||
| 2021-12-31 | $84.00K derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09 | $84.00K derived: sum of 2 quarters · filed 2024-02-09 | $84.00K 8-K · filed 2024-02-09 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 | ||||
| 2020-12-31 | $0.00 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |